摘要
背景:心力衰竭患者(HF)的肾功能显著下降。我们调查了心衰患者肾功能不全的新标志物和炎症状态和心肌重构指数之间的相关性。 方法:参考年龄和性别,我们招募了79名持续心力衰竭患者和79名健康受试者。 用ELISA法测定中性粒细胞明胶酶相关脂质运载蛋白(NGAL)、半胱氨酸蛋白酶抑制剂C、B型利钠肽(BNP)、肿瘤坏死因子α(TNFα)和基质金属蛋白酶9(MMP-9)在血清的水平。使用克罗夫特-高特公式(eCcl)估计肌酐清除率。 左心室射血率是由超声心动图决定。结果: 与健康受试者相比,心力衰竭的患者有明显更高的NGAL (p=0.007) 和半胱氨酸蛋白酶抑制物c水平 (p=0.005)。 在心力衰竭患者中,NGAL水平和肌酐水平,(r=0.40, p<0.001)、 TNFα水平 (r=0.43, p<0.001),、BNP 水平 (r=0.36, p=0.003)、MMP-9 水平 (r=0.37, p=0.02)呈正相关,并且NGAL水平与左心室射血率负相关 (r=-0.23, p=0.045)。有趣的是,NGAL和MMP-9水平之间的关系不受其它因素如年龄、性别、体重指数、左心室射血率、 TNFα 水平和 BNP 水平的影响。此外,心力衰竭患者的半胱氨酸蛋白酶抑制物c水平和eCcl呈负相关(r=-0.21, p=0.04)、 半胱氨酸蛋白酶抑制物c水平与 TNFa、 BNP、MMP-9 水平和及左心室射血率无关(所有因素的p=NS)。结论: NGAL与左心室射血率,心力衰竭患者的心脏重塑和炎症生物标记有关。 这些发现注重反映了在心力衰竭患者中可能常见的肾脏功能障碍发病的机制、发炎过程和心脏功能障碍。
关键词: 生物标志物,心脏重塑,半胱氨酸蛋白酶抑制剂C,心力衰竭,炎症,中性粒细胞明胶酶相关脂质运载蛋白, 肾功能.
Current Medicinal Chemistry
Title:Novel Biomarkers Assessing Renal Function in Heart Failure: Relation to Inflammatory Status and Cardiac Remodelling
Volume: 21 Issue: 34
Author(s): Gerasimos Siasos, Dimitris Tousoulis, Stavroula Michalea, Evangelos Oikonomou, Manolis Vavuranakis, Dimitris Athanasiou, Panagiotis Tourikis, Nikolaos Gouliopoulos, Antigoni Miliou, Konstantinos Mourouzis, Maria Limperi, Savvas Mazaris, Athanasios G Papavassiliou and Christodoulos Stefanadis
Affiliation:
关键词: 生物标志物,心脏重塑,半胱氨酸蛋白酶抑制剂C,心力衰竭,炎症,中性粒细胞明胶酶相关脂质运载蛋白, 肾功能.
摘要: Background: Patients with heart failure (HF) have a significant decline of renal function. We investigate the association between novel biomarkers of renal dysfunction and indices of inflammatory status and cardiac remodeling in patients with HF. Methods: We enrolled 79 consecutive patients with HF and 79 healthy subjects, adjusted for age and sex. Serum levels of neutrophil gelatinase-associated lipocalin (NGAL), cystatin-C, b-type natriuretic peptide (BNP), tumor necrosis factor alpha (TNFα) and matrix metalloproteinase-9 (MMP-9) were measured by ELISA. Creatinine clearance was estimated using Cockcroft-Gault formula (eCcl). Left ventricular ejection fraction was determined by echocardiography. Results: Patients with HF, compared to healthy subjects, had significantly higher NGAL (p=0.007) and cystatin-C levels (p=0.005). In HF patients, NGAL levels were positively correlated with Creatinine levels (r=0.40, p<0.001), TNFa levels (r=0.43, p<0.001), BNP levels (r=0.36, p=0.003), MMP-9 levels (r=0.37, p=0.02) and inversely correlated with left ventricle ejection fraction (r=-0.23, p=0.045). Interestingly, the association between NGAL and MMP-9 levels was independent from confounders such as age, gender, left ventricle ejection fraction, body mass index, TNFα levels, and BNP levels. Moreover, in HF patients, cystatin-C levels were inversely correlated with eCcl (r=-0.21, p=0.04). Cystatin-C levels were not correlated with TNFa, BNP, MMP-9 levels and with left ventricle ejection fraction (p=NS for all). Conclusions: NGAL is associated with left ventricle ejection fraction, and biomarkers of inflammation and cardiac remodeling in patients with HF. These findings highlight a possible common pathogenetic mechanism of renal dysfunction, inflammatory process and cardiac dysfunction in HF.
Export Options
About this article
Cite this article as:
Siasos Gerasimos, Tousoulis Dimitris, Michalea Stavroula, Oikonomou Evangelos, Vavuranakis Manolis, Athanasiou Dimitris, Tourikis Panagiotis, Gouliopoulos Nikolaos, Miliou Antigoni, Mourouzis Konstantinos, Limperi Maria, Mazaris Savvas, Papavassiliou G Athanasios and Stefanadis Christodoulos, Novel Biomarkers Assessing Renal Function in Heart Failure: Relation to Inflammatory Status and Cardiac Remodelling, Current Medicinal Chemistry 2014; 21 (34) . https://dx.doi.org/10.2174/0929867321666140826114656
DOI https://dx.doi.org/10.2174/0929867321666140826114656 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering
Current Drug Targets Editorial [Hot Topic Intracellular Calcium Signaling: Holding the Balance between Health and Disease Guest Editor: Luca Munaron]
Current Medicinal Chemistry TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews The Effect of Resveratrol dose and Duration of Treatment on Blood Pressure in Patients with Cardiovascular Disorders: A Systematic Review
Current Drug Discovery Technologies Molecular Imaging: Its Application In Cardiovascular Diagnosis
Current Pharmaceutical Design Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design The Rabbit as an Experimental and Production Animal: From Genomics to Proteomics
Current Protein & Peptide Science The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Editorial (Thematic Issue: New Therapeutic Targets in Clinical Medicine)
Current Pharmaceutical Design Renalase is Removed by Kidneys and During Dialysis – Excess Related to CKD Complications?
Current Vascular Pharmacology Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology The CLCA Gene Family: Putative Therapeutic Target for Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Chemotherapy and Cardiotoxicity in Hematologic Malignancies
Current Cancer Drug Targets HspB1 Dynamic Phospho-Oligomeric Structure Dependent Interactome as Cancer Therapeutic Target
Current Molecular Medicine Effects of Tea Catechins on Inflammation-Related Cardiovascular Diseases
Current Immunology Reviews (Discontinued)